抗肿瘤靶向和免疫治疗致银屑病研究进展

doi:10.35541/cjd.20210442

中华皮肤科杂志 ›› 2022, e20210442.doi: 10.35541/cjd.20210442

• 综述 • 下一篇

抗肿瘤靶向和免疫治疗致银屑病研究进展

隋长霖常晓赵琪朱威

首都医科大学宣武医院皮肤科，北京 100053

收稿日期:2021-06-10 修回日期:2022-03-18 发布日期:2022-05-06
通讯作者: 朱威 E-mail:zhuwei@xwh.ccmu.edu.cn

Psoriasis induced by anti-tumor targeted therapy and immunotherapy

Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei

Department of Dermatology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Received:2021-06-10 Revised:2022-03-18 Published:2022-05-06
Contact: Zhu Wei E-mail:zhuwei@xwh.ccmu.edu.cn

摘要/Abstract

摘要： 【摘要】近年来靶向和免疫治疗在抗肿瘤治疗中的应用越来越广，不断有此类药物引起或加重银屑病的报道。该文根据药物的作用靶点与可能机制，总结与评价诱发或加重银屑病的相关药物，包括程序性死亡受体1抑制剂、表皮生长因子受体抑制剂、人表皮生长因子受体2抑制剂、CD20单抗、磷脂酰肌醇3激酶δ抑制剂以及多靶点药物。多数病例银屑病发生与药物可能或很可能相关，仅少数存在明确的因果关系。

关键词: 银屑病, 药物毒性, 抗肿瘤药, 分子靶向治疗, 免疫疗法

Abstract: 【Abstract】 In recent years, targeted therapy and immunotherapy have been applied more and more widely in tumor treatment, and reports on psoriasis induced or exacerbated by these drugs have emerged continuously. This review summarizes and evaluates targeted therapeutic drugs and immunotherapeutic drugs that allegedly induce or aggravate psoriasis according to their targets and possible mechanisms, including programmed death receptor 1 inhibitors, epidermal growth factor receptor inhibitors, human epidermal growth factor receptor 2 inhibitors, anti-CD20 monoclonal antibodies, phosphoinositide 3-kinase δ inhibitors and multi-targeted drugs. In most cases, the relationships between drugs and the occurrence of psoriasis are possible or probable, and in only a few cases the causality is certain.

Key words: Psoriasis, Drug toxicity, Antineoplastic agents, Molecular targeted therapy, Immunotherapy

隋长霖常晓赵琪朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2022,e20210442. doi:10.35541/cjd.20210442

Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy[J]. Chinese Journal of Dermatology,2022,e20210442. doi:10.35541/cjd.20210442

参考文献 54

［1］	Zaki SA. Adverse drug reaction and causality assessment scales［J］. Lung India, 2011,28（2）:152⁃153. doi: 10.4103/0970⁃2113. 80343.
［2］	George A, George R. Nivolumab （PD⁃1 inhibitor） induced exacerbation of psoriasis［J］. Indian Dermatol Online J, 2020,11（2）:261⁃262. doi: 10.4103/idoj.IDOJ_47_19.
［3］	Yamamoto T. Anti⁃programmed cell death⁃1⁃induced plaque and guttate psoriasis［J］. Indian J Dermatol, 2018, 63（1）:88⁃89. doi: 10.4103/ijd.IJD_46_17.
［4］	Mayor Ibarguren A, Enrique EA, Diana PL, et al. Apremilast for immune checkpoint inhibitor⁃induced psoriasis: a case series［J］. JAAD Case Rep, 2021,11:84⁃89. doi: 10.1016/j.jdcr.2021.03.015.
［5］	Politi A, Angelos D, Mauri D, et al. A case report of psoriasis flare following immunotherapy: report of an important entity and literature review［J］. SAGE Open Med Case Rep, 2020,8:2050313X19897707. doi: 10.1177/2050313X19897707.
［6］	Mullangi S, Ponnam S, Lekkala MR, et al. A case of de novo psoriasis secondary to nivolumab in a patient with metastatic renal cell carcinoma［J］. Cureus, 2021,13（6）:e15703. doi: 10.7759/cureus.15703.
［7］	Glinos GD, Fisher WS, Morr CS, et al. Nivolumab⁃induced psoriasis successfully treated with risankizumab⁃rzaa in a patient with stage III melanoma［J］. JAAD Case Rep, 2021,11:74⁃77. doi: 10.1016/j.jdcr.2021.03.029.
［8］	Marti⁃Marti I, Gómez S, Riera⁃Monroig J, et al. Rupioid psoriasis induced by pembrolizumab［J］. Indian J Dermatol Venereol Leprol, 2020,86（5）:580⁃582. doi: 10.4103/ijdvl.IJDVL_1067_19.
［9］	Scarfì F, Lacava R, Patrizi A, et al. Follicular psoriasis induced by pembrolizumab in a patient with advanced non⁃small⁃cell lung cancer［J］. Int J Dermatol, 2019,58（8）:e151⁃e152. doi: 10.1111/ijd.14457.
［10］	Siciliano MA, Dastoli S, d′Apolito M, et al. Pembrolizumab⁃induced psoriasis in metastatic melanoma: activity and safety of apremilast, a case report［J］. Front Oncol, 2020,10:579445. doi: 10.3389/fonc.2020.579445.
［11］	Takama H, Shibata T, Ando Y, et al. Pembrolizumab⁃induced psoriasis vulgaris successfully treated with apremilast［J］. Eur J Dermatol, 2020,30（2）:188⁃190. doi: 10.1684/ejd.2020.3723.
［12］	Monsour EP, Pothen J, Balaraman R. A novel approach to the treatment of pembrolizumab⁃induced psoriasis exacerbation: a case report［J］. Cureus, 2019,11（10）:e5824. doi: 10.7759/cureus.5824.
［13］	Huang PW, Chu CY. Pembrolizumab⁃induced linear psoriasis［J］. Lung Cancer, 2020,146:378⁃379. doi: 10.1016/j.lungcan. 2020.06.012.
［14］	Sahuquillo⁃Torralba A, Ballester⁃Sánchez R, Pujol⁃Marco C, et al. Pembrolizumab: a new drug that can induce exacerbations of psoriasis［J］. Actas Dermosifiliogr, 2016,107（3）:264⁃266. doi: 10.1016/j.ad.2015.07.012.
［15］	Sui CL, Lin XF, He L, et al. Dermoscopic features of acutely exacerbated plaque psoriasis induced by anti⁃programmed death⁃1 for lung cancer［J］. Chin Med J （Engl）, 2020,133（17）:2123⁃2125. doi: 10.1097/CM9.0000000000000958.
［16］	De Bock M, Hulstaert E, Kruse V, et al. Psoriasis vulgaris exacerbation during treatment with a PD⁃1 checkpoint inhibitor: case report and literature review［J］. Case Rep Dermatol, 2018,10（2）:190⁃197. doi: 10.1159/000491572.
［17］	Nonomura Y, Otsuka A, Ohtsuka M, et al. ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab［J］. J Eur Acad Dermatol Venereol, 2017,31（2）:e100⁃e101. doi: 10.1111/jdv. 13818.
［18］	Tanaka R, Ichimura Y, Kubota N, et al. Activation of CD8 T cells accelerates anti⁃PD⁃1 antibody⁃induced psoriasis⁃like dermatitis through IL⁃6［J］. Commun Biol, 2020,3（1）:571. doi: 10.1038/s42003⁃020⁃01308⁃2.
［19］	Bonigen J, Raynaud⁃Donzel C, Hureaux J, et al. Anti⁃PD1⁃induced psoriasis: a study of 21 patients［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:e254⁃e257. doi: 10.1111/jdv. 14011.
［20］	Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy［J］. Am J Clin Dermatol, 2018,19（3）:345⁃361. doi: 10.1007/s40257⁃017⁃0336⁃3.
［21］	Halle BR, Betof Warner A, Zaman FY, et al. Immune checkpoint inhibitors in patients with pre⁃existing psoriasis: safety and efficacy［J］. J Immunother Cancer, 2021,9（10）:e003066. doi: 10.1136/jitc⁃2021⁃003066.
［22］	Marinello E, Pastorelli D, Alaibac M. A case of psoriasis pustolosa palmaris induced by cetuximab［J］. BMJ Case Rep, 2016,2016:bcr2016214582. doi: 10.1136/bcr⁃2016⁃214582.
［23］	Kamaria M, Shea CR, Chin RK, et al. Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab［J］. Clin Exp Dermatol, 2014,39（5）:604⁃607. doi: 10.1111/ced.12341.
［24］	Abe S, Ueno M, Nishitani M, et al. Citrus sudachi peel extract suppresses cell proliferation and promotes the differentiation of keratinocytes through inhibition of the EGFR⁃ERK signaling pathway［J］. Biomolecules, 2020,10（10）:1468. doi: 10.3390/biom10101468.
［25］	Le A, Azouz A, Thomas S, et al. JNK1 signaling downstream of the EGFR pathway contributes to aldara®⁃induced skin inflammation［J］. Front Immunol, 2020,11:604785. doi: 10.3389/fimmu.2020.604785.
［26］	Furue K, Ito T, Tanaka Y, et al. The EGFR⁃ERK/JNK⁃CCL20 pathway in scratched keratinocytes may underpin koebnerization in psoriasis patients［J］. Int J Mol Sci, 2020,21（2）:434. doi: 10.3390/ijms21020434.
［27］	de Lorenzi C, Kaya G, Quenan S. Psoriasis induced by trastuzumab therapy［J］. Eur J Dermatol, 2018,28（5）:702⁃704. doi: 10.1684/ejd.2018.3395.
［28］	Kim DW, Park SK, Woo SH, et al. New⁃onset psoriasis induced by rituximab therapy for non⁃Hodgkin lymphoma in a child［J］. Eur J Dermatol, 2016,26（2）:190⁃191. doi: 10.1684/ejd.2015. 2705.
［29］	Haller C, Cozzio A, von Kempis J, et al. Successful treatment of rituximab⁃associated palmoplantar pustulosis with apremilast in a patient with seropositive rheumatoid arthritis［J］. J Clin Rheumatol, 2021,27（7）:e289⁃e290. doi: 10.1097/RHU.000000 0000001415.
［30］	Koumaki D, Koumaki V, Haniotis V, et al. Erythrodermic psoriasis after rituximab treatment in a patient with autoimmune hemolytic anemia［J］. Indian J Dermatol, 2021,66（1）:108⁃112. doi: 10.4103/ijd.IJD_336_19.
［31］	Fiorillo L, Wang C, Hemmati I. Rituximab induced psoriasis in an infant［J］. Pediatr Dermatol, 2014,31（6）:e149⁃e151. doi: 10. 1111/pde.12437.
［32］	Guidelli GM, Fioravanti A, Rubegni P, et al. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature［J］. Rheumatol Int, 2013,33（11）:2927⁃2930. doi: 10.1007/s00296⁃012⁃2581⁃3.
［33］	Chang YS, Lee HT, Chen WS, et al. Treatment of psoriasis with rituximab［J］. J Am Acad Dermatol, 2012,66（5）:e184⁃e185. doi: 10.1016/j.jaad.2010.08.007.
［34］	Şimşek T, Yıldırım N, Efe B, et al. Rituximab treatment in a patient with active Graves′ orbitopathy and psoriasis［J］. Turk J Ophthalmol, 2017,47（1）:42⁃46. doi: 10.4274/tjo.26780.
［35］	Niu J, Zhai Z, Hao F, et al. Dissection of a circulating CD3+ CD20+ T cell subpopulation in patients with psoriasis［J］. Clin Exp Immunol, 2018,192（2）:206⁃212. doi: 10.1111/cei. 13106.
［36］	Alahmari HS, Alhowaish NY, Omair MA. Rituximab⁃induced psoriasis in a patient with granulomatosis with polyangitis treated with adalimumab［J］. Case Rep Rheumatol, 2019,2019:5450863. doi: 10.1155/2019/5450863.
［37］	Machan S, Plaza C, Pérez⁃González Y, et al. Management of psoriasis⁃like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report［J］. J Med Case Rep, 2020,14（1）:35. doi: 10.1186/s13256⁃020⁃2344⁃9.
［38］	Pesqué D, Sanchez⁃Gonzalez B, Gallardo F, et al. Psoriasiform eruption secondary to PI3K⁃delta inhibitor: expanding the spectrum of psoriasiform paradoxical reactions?［J］. Acta Derm Venereol, 2021,101（3）:adv00418. doi: 10.2340/00015555⁃3783.
［39］	Mercurio L, Morelli M, Scarponi C, et al. PI3Kδ sustains keratinocyte hyperproliferation and epithelial inflammation: implications for a topically druggable target in psoriasis［J］. Cells, 2021,10（10）:2636. doi: 10.3390/cells10102636.
［40］	Shim JH, Oh SH, Jun JY, et al. Exacerbation of psoriasis after imatinib mesylate treatment［J］. Ann Dermatol, 2016,28（3）:409⁃411. doi: 10.5021/ad.2016.28.3.409.
［41］	Thachil J. T⁃regulatory cell response in psoriasis and changes with imatinib therapy［J］. Clin Exp Dermatol, 2009,34（8）:e1022. doi: 10.1111/j.1365⁃2230.2009.03696.x.
［42］	Woo SM, Huh CH, Park KC, et al. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib［J］. J Dermatol, 2007,34（10）:724⁃726. doi: 10.1111/j.1346⁃8138. 2007.00369.x.
［43］	Jain A. Imatinib Induced Complete Remission of psoriasis in a patient with chronic myeloid leukemia［J］. Indian J Hematol Blood Transfus, 2020,36（1）:198⁃199. doi: 10.1007/s12288⁃019⁃01162⁃1.
［44］	Kaur S, Arora AK, Sekhon JS, et al. Nilotinib⁃induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate［J］. Indian J Dermatol Venereol Leprol, 2015,81（2）:216⁃218. doi: 10.4103/0378⁃6323.152311.
［45］	Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src⁃family kinase LCK and T⁃cell function in vitro［J］. J Cell Mol Med, 2009,13（3）:599⁃601. doi: 10.1111/j.1582⁃4934.2009.00500_1.x.
［46］	Fei F, Yu Y, Schmitt A, et al. Effects of nilotinib on regulatory T cells: the dose matters［J］. Mol Cancer, 2010,9:22. doi: 10.1186/1476⁃4598⁃9⁃22.
［47］	Adachi T, Hiraoka A, Okazaki H, et al. Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma［J］. Clin J Gastroenterol, 2020,13（5）:891⁃895. doi: 10.1007/s12328⁃020⁃01134⁃3.
［48］	Ohashi T, Yamamoto T. Exacerbation of psoriasis with pustulation by sorafenib in a patient with metastatic hepatocellular carcinoma［J］. Indian J Dermatol, 2019,64（1）:75⁃77. doi: 10.4103/ijd.IJD_16_17.
［49］	Zhao D, Zhai B, He C, et al. Upregulation of HIF⁃2α induced by sorafenib contributes to the resistance by activating the TGF⁃α/EGFR pathway in hepatocellular carcinoma cells［J］. Cell Signal, 2014,26（5）:1030⁃1039. doi: 10.1016/j.cellsig.2014.01. 026.
［50］	Rosenberger C, Solovan C, Rosenberger AD, et al. Upregulation of hypoxia⁃inducible factors in normal and psoriatic skin［J］. J Invest Dermatol, 2007,127（10）:2445⁃2452. doi: 10.1038/sj.jid. 5700874.
［51］	Tang W, Long T, Li F, et al. HIF⁃1α may promote glycolysis in psoriasis vulgaris via upregulation of CD147 and GLUT1［J］. J Cent South Univ （Med Sci）, 2021,46（4）:333⁃344. doi: 10.11817/ j.issn.1672⁃7347.2021.200010.
［52］	van Kester MS, Luelmo S, Vermeer MH, et al. Remission of psoriasis during treatment with sorafenib［J］. JAAD Case Rep, 2018,4（10）:1065⁃1067. doi: 10.1016/j.jdcr.2018.09.009.
［53］	Sally R, Ugonabo N, Nguyen A, et al. Lenvatinib⁃induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma［J］. JAAD Case Rep, 2021,15:1⁃3. doi: 10.1016/j.jdcr.2021.07.001.
［54］	Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1⁃6 hepatocellular carcinoma model［J］. Cancer Sci, 2018,109（12）:3993⁃4002. doi: 10.1111/cas.13806.

[1]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[2]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[3]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[4]	张元文孙从乾潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024, 57(5): 471-475.
[5]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[6]	姚曼雪周乃慧. 程序性细胞死亡蛋白1/程序性细胞死亡蛋白配体1抑制剂相关的Stevens-Johnson综合征/中毒性表皮坏死松解症研究进展 [J]. 中华皮肤科杂志, 2024, 0(3): 20220644-e20220644.
[7]	叶慧薛如君张锡宝. 生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220795-e20220795.
[8]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[9]	王煜坤刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660.
[10]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[11]	吴玉冰王晓宇安彬祎吴莹莹桑红孔庆涛. 环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子信号通路在银屑病发病中的作用[J]. 中华皮肤科杂志, 2024, 0(3): 20230394-e20230394.
[12]	朱婷婷张学军. 阿普米司特在斑块状银屑病治疗中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230448-e20230448.
[13]	郝丹王怡怡肖月闫薇李薇. [开放获取] 特殊部位银屑病系统治疗临床研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230190-e20230190.
[14]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 97-108.
[15]	窦进法王建波张帅李建国刘鸿伟张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 0(2): 20230167-e20230167.

抗肿瘤靶向和免疫治疗致银屑病研究进展

Psoriasis induced by anti-tumor targeted therapy and immunotherapy

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 54

相关文章 15

Metrics

本文评价

推荐阅读 10